Best of EASL White Nights
|
|
- Mervyn Cox
- 6 years ago
- Views:
Transcription
1 Best of EASL White Nights Saint Petersburg 8 June 2017 Patients with HCC and HCV:do we really need to cure HCV? Massimo Colombo, MD Center for Translational Research in Hepatology,Humanitas Hospital, Rozzano, Italy. EASL International Liver Foundation, Geneva, Switzerland
2 Financial Disclosures Grant and research support: BMS, Gilead Science Advisory committees: Merck, Roche, Novartis, Bayer, BMS, Gilead Science, Tibotec, Vertex, Janssen Cilag, Achillion, Lundbeck, GSK, GenSpera, AbbVie, Alfa Wassermann Speaking and teaching: Tibotec, Roche, Novartis, Bayer, BMS, Gilead Science, Vertex, Merck, Janssen, AbbVie
3 Antiviral Therapy for HCV and Risk of Liver Cancer Patient and HCV factors associated with increased risk of HCC Chemoprevention with IFN of HCV-related HCC Occurrence and recurrence of HCC after a SVR to DAA Recommendations from International Societies HCV, hepatitis C virus
4 Increased Mortality of HCV Patients from Liver Cancer The REVEAL Cohort Study Causes of Death Multivariate-adjusted HR (95%CI) All causes 1.89 ( ) All liver-related ( ) HCC ( ) All extrahepatic diseases 1.35 ( ) All cancer, except HCC 1.32 ( ) Cardiovascular diseases 1.50 ( ) Nephritis/nephrosis 2.77 ( ) Lee et al, J Infect Dis 2012;206: HR hazard ratio CI confidence intervals
5 Direct vs Indirect Mechanisms of Carcinogenesis in the HCV-infected Liver Direct Indirect HCV infection deregulates host cell cycle checkpoints Immune- and virusmediated oxidative stress and DNA damage Infected cells accumulate mutations, eventually resulting in transformation Immune- or virus-mediated apoptosis Compensatory proliferation and reinfection Uninfected normal hepatocyte HCV-infected normal hepatocyte Transformed hepatocyte HCV-infected, transformed hepatocyte Uninfected bystander cells accumulate mutations in an environment of inflammation and oxidative stress Proliferation of transformed hepatocytes Lemon SM, Gastroenterology 2012;142:1274 8
6 Factors Associated with Increased Risk of HCC in HCV Patients.The HCV VA Cohort Patient characteristic Cirrhosis HCC Events, No. (%) 17,926 (14.5%) 4,517 (3.5%) Male sex 1.35 ( ) 3.41 ( ) Age 1.02 ( ) 1.07 ( ) Race White Black Other HCV genotype Other 1 (reference) 0.54 ( ) 0.73 ( ) 1 (reference) 0.64 ( ) 1.24 ( ) 0.87 ( ) 1 (reference) 0.73 ( ) 0.80 ( ) 1 (reference) 0.52 ( ) 1.63 ( ) 0.77 ( ) Diabetes at baseline 1.38 ( ) 1.31 ( ) McCombs, JAMA Intern Med 2014;174:
7 Alcohol Boosts the Risk of HCC in HCV Patients The Cleveland Clinic A Prospective Study of HCC in Cirrhotic Patients Evaluated for OLT Social Alcohol Intake vs No Alcohol HCV NASH Alcohol Alcohol No Alcohol No Alcohol Ascha et al, Hepatology 2010;51:1972-8
8 HCV and Host-related Molecular Changes Associated to HCC Development Molecular change Assay Significance Author HCV-1b core glu70 Dir.sequencing HR 10.5 Akuta 2011 NBS1 CC PCR-RFLP HR 2.27 Huang genes AT/TT GWAS 47% at 10 yr Ono 2017 TLL1 GWAS OR 1.78 Matsura 2017 Histone changes GWAS (+) after SVR Juhling 2017 Hypermethilation p16 PCR (+) after SVR Hayashi 2008
9 Antiviral Therapy for HCV and Risk of Liver Cancer Patient and HCV factors associated with increased risk of HCC Chemoprevention with IFN of HCV-related HCC Occurrence and recurrence of HCC after a SVR to DAA Recommendations from International Societies HCV, hepatitis C virus
10 Reduced Incidence of HCC Following an SVR to IFN A Meta-analysis of 59 Studies Bang and Song BMC Gastroenterology 2017,17;46
11 Predictors of HCC Development in SVR Patients The HCV VA Cohort 22,028 patients treated with Peg-IFN ± RBV( ) HCC x 1000 pp x yr : 3.27 SVR vs 13.2 non-svr (HR: 0.358) Predictor of HCC Following SVR* HR (95% CI) P Value Cirrhosis at SVR 4.45 ( ) < Age at SVR, year (vs < 55 year) ( ) or older 4.69 ( ) Diabetes 2.07 ( ) HCV genotype (vs genotype 1) HCV ( ) HCV ( ) *Cox proportional hazards model adjusted for competing risk of death. El-Serag HB, et al Hepatology 2016
12 Life-long Risk of HCC in Cirrhotics with a SVR to IFN A Cohort Study in Milan & Palermo Hepatocellular Carcinoma Liver Decompensation 10.3% at 10 yrs 23.7% at 20 yrs 5.2% at 10 yrs 13.6% at 20 yrs yr yr Bruno S et al J Hepatol 2016
13 Interferon-Induced Regression of Cirrhosis Does Not Prevent HCC in HCV Patients Second biopsy in 38 patients 5 yrs after SVR to Peg IFN-RBV : 6-monthly surveillance* Six monthly surveillance of the SVR cohort ** Follow-up months from SVR HCC 3/23 (13%) regressors 2/15 (13%) non regressors Other site malignancies 1/23(4%) regressors 1/15((6%) non regressors *D Ambrosio et al Hepatology 2012; ** D Ambrosio et al EASL ILC Amsterdam 2017
14 Antiviral Therapy for HCV and Risk of Liver Cancer Patient and HCV factors associated with increased risk of HCC Chemoprevention with IFN of HCV-related HCC Occurrence and recurrence of HCC after a SVR to DAA Recommendations from International Societies HCV, hepatitis C virus
15 De-novo HCC After DAA Therapy of HCV Cirrhosis Author HCC /Cirrhosis Follow-up Months HCC Incidence Kozbial 16/ % (4.8% SVR) Cardoso 4/ % (all SVR) Conti 9/ % (2.5% SVR) Cheung 38/ % SVR 6.7% NR 8.9% Untreated Kobayashi 2/ % Kozbial et al. J Hepatol 2016, Cardoso et al. J Hepatol 2016, Conti et al. J Hepatol 2016, Cheung et al. J Hepatol Kobayashi et al J Med Virol2017 ;89:476-83
16 De-novo HCC After DAA Therapy of HCV Cirrhosis Population Studies in Italy The Navigator Study Veneto* The Resist HCV Study Sicily** Cohort 3,381 F3 / F4 Cohort 1,903 F3 / F4 HCC 1.6 x 100 pp x yr HCC 2.7 x 100 pp x yr HCC Pattern 51% < Milan HCC Pattern 89% < Milan 39% > Milan 11% > Milan *Romano et al. AASLD Meeting Boston 2016 **Calvaruso et al EASL HCC Summit Geneva 2017
17 De Novo HCC Following a SVR to DAA Therapy Reports From EASL ILC 2017 Courtesy of Prof M.Bourilere
18 The Incidence of HCC is Reduced in HCV Patients After a SVR to DAA. The VA Cohort Study period Jan 2015 march 2016 Patients 22,579 on IFN-free DAA (37% cirrh.,44% DMT2) Follow up /- 3.6 months Developed HCC 369 (88 during DAA) HCC risk x 100 PY * SVR 0.89 vs non-svr 3.65 Kanwall et al AASLD DDW 2017 # 419 *after exclusion of 88 HCC during DAA
19 Patients (%) UK Expanded Access to SOF/NS5A for 12 Weeks in Advanced Cirrhosis due to HCV Outcomes in 329 SVR patients after 3 months therapy plus 12 months follow-up Months 0-6 Months 6-15 p < 0, p < 0,05 De novo HCC Foster et al, J Hepatol 2016: 64,
20 No evidence of Increased Occurrence of HCC After DAA Therapy for HCV Meta-analysis of 41 studies,13 with DAA only,13,875 patients Waziry R et al EASL ILC Amsterdam 2017
21 HCC Occurrence According to Risk Factors.RESIST Calvaruso V et al EASL ILC Amsterdam 2017
22 HCC Occurrence Following SVR to IFN or DAA A Meta-analysis (100 pp x yr) author year IFN % ES (95% CI) Weight DAA Ogawa D'Ambrosio Bruno (1.75, 7.70) 0.71 (0.23, 2.20) 1.74 (0.83, 3.64) author year ES (95% CI) % Weight Mallet (0.25, 2.43) 4.41 Cardoso Yu Hung (0.75, 3.70) 2.04 (1.06, 3.93) 2.22 (0.92, 5.34) Cardoso Conti (2.78, 19.74) 4.51 (2.35, 8.67) Morgan (0.05, 0.80) 3.27 Rinaldi (4.91, 21.59) Aleman Cheinquer Moon (0.46, 2.29) 0.98 (0.14, 6.98) 1.12 (0.16, 7.94) Kozbial Lei-Zeng (0.97, 3.35) 0.04 (0.00, 1.30e+07) Fernandez-Rodriguez (0.41, 2.37) 6.12 Romano (1.22, 2.59) Janjua Rutter Velosa (0.33, 1.64) 0.95 (0.48, 1.91) 0.36 (0.05, 2.56) Affronti Muir (1.25, 8.88) 0.12 (0.02, 0.85) Nahon (0.61, 1.28) Carrat (2.67, 4.08) Marco 2016 Overall (I-squared = 45.7%, p = 0.021) NOTE: Weights are from random effects analysis 0.85 (0.41, 1.78) 7.34 Overall (I-squared = 78.3%, p = 0.000) 1.14 (0.86, 1.52) (0.86, 1.52) NOTE: Weights are from random effects analysis 3.09 (1.92, 4.96) 3.09 (1.92, 4.96) HCC occurrence rate (/100 person-years) HCC occurrence rate (/100 person-years) Waziry R et al EASL ILC Amsterdam 2017
23 Recurrence of HCC after Resection or Ablation The Storm Study Resection n.900 Local ablation n.459 Number of nodules vs vs vs 4 Bruix et al Lancet Oncology 2015
24 HCC Recurrence in Patients with Cirrhosis Following IFN-free Therapy for HCV Author CR after N.Pt. Months from Recurrence x100 pp/mo. Res / RFA CR to DAA Reig (27.6%) - Conti (28.8%) - Pol (13%) (7.7%) 1.11 Zavaglia (3.2%) - Virlogeoux 2017* + 23 vs ,4 11(48%) vs 33(73%) 1.7 Reig 2017** (27.3%) - J Hepatolol 2016 and 2017 * Liver Intern 2017 ** EASL ILC Amsterdam 2017
25 A Retrospective Multicenter Confirmatory Study of HCC Recurrence After DAA. Whole cohort (n=77) Median follow-up,months 12.4 (IQR: ) HCC progression n= 24 (31.2%) Death n=5 (6.5%) HCC recurrence (n=24) Median months between start DAA and 1 st HCC recurrence 3.5 (IQR: 2-7.6) 2 nd recurrence / progression n=10 Median months between 1 st - 2 nd HCC recurrence/progression 6 (IQR: ) Recurrence/progression within 6 months of 1 st recurrence 6/20 (30%) 16.7% BSC 37.5 % Ablation Resection LT 45.8 % TACE Sorafenib Regorafenib RE Clinical Trials Death n=5 (20.8%) Reig M et al EASL ILC Amsterdam 2017
26 Courtesy of Prof M.Bourliere HCC Recurrence After DAA Therapy Reports From EASL ILC 2017
27 No evidence of Increased Recurrence of HCC After DAA Therapy for HCV Meta-analysis of 41 studies,13 with DAA only,13,875 patients Waziry R et al EASL ILC Amsterdam 2017
28 HCC Recurrence Following SVR to IFN or DAA A Meta-analysis(100 pp x yr) author IFN DAA % year ES (95% CI) Weight author year ES (95% CI) % Weight Hagihara (4.58, 18.30) Conti Pol, CO (28.49, 73.71) 8.11 (5.43, 12.10) Kanogawa (3.49, 12.05) Pol, CO (0.62, 31.20) 8.86 Kunimoto (4.82, 12.84) Pol, CO (1.35, 5.92) Jeong (7.14, 24.65) Reig (33.23, 88.53) Saito (6.14, 27.01) Rinaldi Minami (3.76, ) (9.43, 46.70) Sanefuji (4.30, 41.34) 4.84 Torres (0.00, 2.28e+07) 0.20 Minami 2016 Overall (I-squared = 0.0%, p = 0.638) NOTE: Weights are from random effects analysis (4.05, 16.19) (7.18, 11.81) (7.18, 11.81) Zavaglia 2016 Lei-Zeng 2016 Overall (I-squared = 89.1%, p = 0.000) NOTE: Weights are from random effects analysis (0.20, 10.07) (0.00, 2.60e+07) (5.00, 29.46) (5.00, 29.46) HCC recurrence rate (/100 person-years) HCC recurrence rate (/100 person-years) Waziry et al EASL ILC Amsterdam 2017
29 Post-transplant HCC Recurrence Following IFN-free Therapy of HCV in the Wait List Study Pts HCC at Explant From HCC Dg Recurrence to LT Yang % > Milan n.a. N.5 = 27.8% * 4-17 mo.post-lt 60% MVI Donato % > Milan 3-38 mo. N.3 =10.7% * 35% complete necrosis mo. post-lt 35% MVI 100% MVI * All bridged with RFA or TACE Yang et al J Hepatol 2016 ; Donato et al J Hepatol in press
30 Reduced Recurrence of HCC in Patients Treated with DAA Post-transplant n.50 n.27 n.74 Nyiazi et al AASLD DDW 2017
31 Increased Occurrence and Recurrence of HCC after IFN-free Therapy. Facts or Artifacts? Hypothesis - a swift removal of HCV might cause: Impairment of NK cells-mediated tumor immuno-surveillance. TRAIL-related de-escalation of apoptosis. Impaired tumor control following reduction of non-specific inflammatory cells. Warning : confounding factors and methodological issues in the cohorts investigated. Debes J D et al Lancet Gastroent Hepatol in press
32 Antiviral Therapy for HCV and Risk of Liver Cancer Patient and HCV factors associated with increased risk of HCC Chemoprevention with IFN of HCV-related HCC Occurrence and recurrence of HCC after a SVR to DAA Recommendations from International Societies HCV, hepatitis C virus
33 Surveillance for HCC of Patients With an SVR AASLD/ISDA:Updated Recommendations Surveillance for HCC with twice-yearly US examination of Metavir F3 or F4 Rating : Class I, Level C Caveats Diagnosis by Liver Stiffness of Metavir F3 and F4 is inaccurate in viremic patients and mostly inaccurate in SVR patients. AASLD/IDSA HCV Guidance: Recommendations for Testing,Managing,and Treating Hepatitis C
34 Surveillance of HCC of Patients With an SVR EASL : Updated Recommendations Non-cirrhotic patients with SVR should be retested for ALT and HCV RNA (or HCV core antigen) at 48 weeks post-treatment, then discharged if ALT is normal and HCV RNA is negative (A1) Patients with advanced fibrosis (F3) and cirrhotic patients with SVR should undergo surveillance for HCC every 6 months by ultrasound (A1) EASL Clinical Practice Guidelines, J Hepatol 2016
35
36 Surveillance for HCC of Patients With an SVR AGA Recommendations AGA Institute Clinical Practice Update Expert Review for SVR Patients Jacobson I et al Gastroenterol 2017
37 Low Sensitivity of Fibroscan (TE) to Detect Cirrhosis Regression in SVR Patients Diagnosis of Residual Cirrhosis by Fibroscan Is Biased By Liver Morphometry TE vs liver biopsy TE vs liver biopsy TE > 12Kpa TE < 12Kpa 8/9 F4 by LB 5/24 F4 by LB Cut off of 12 Kpa for Cirrhosis: Specificity = 95% (85-100%) Sensitivity = 61% (35-87%) D Ambrosio et al, J Hepatol 2013;59:
38 Persistence of HCV-RNA in the Liver of Patients Achieving a SVR to DAA Explants from 39 SVR patients > 26(67%) had HCV-RNA (LLD of IU/ML) > Liver HCV-RNA more likely in patients with shorter therapy and/or shorter RNA negative window to liver transplantation > Down-regulation of type II & III IFN and ISGs > Delayed clearance from the liver Confirmatory studies El Masry et al Gastroenterology 2017 Wintcamle et al Clin Gastroent Hepatol 2017 Gambato et al Gastroenterology 2016;15:1535
39 AFP Surveillance of HCV Cirrhosis with SVR. True (TPR) and False (FPR) Positive Results Naives at VA : 12,124 cirrhosis SVR : 3,979 cirrhosis 902 incident HCC 168 incident HCC Tayob et al AASLD DDW 2017
40 Decision-tree and Random Forest Models Prospective ANRS CO12 CirVir Audureau et al EASL ILC Amsterdam 2017
41 A Multicenter Study of HCC Recurrence Following IFN-free Therapy of Hepatitis C Fifty six patients treated with Resection(39%),Ablation(39%) or TA(C)E(21%) HCC diagnosis : 21 months from HCC Tx and 9.3 months from DAA Tx DFS = 75% at month 6 after DAA therapy and 56% at month 24 cumulatively. Kolby et al J Hepatol 2017
42 HCC Occurrence After IFN vs DAA Therapy * After adjustment for: age, gender, ethnicity, Child-Pugh score, thrombocytopenia, AFP, HCV genotype, number of prior treatment episodes, and clinic location Innes et al EASL ILC Amsterdam 2017
43 Efficacy of IFN-free HCV Therapy in Patients with Active HCC. VA Cohort Beste L et al J Hepatol in press
44 SVR is Associated with a Reduced Mortality HCC and Liver Transplant Systematic review of 129 studies of IFN therapy in 34,563 HCV patients Achieving SVR was associated with: 62 84% reduction in all-cause mortality 68 79% reduction in risk of HCC 90% reduction in risk of liver transplant Saleem J, et al. Hepatology 2014:60:218A-219A
45 Competing Risk Analysis on Outcome after Hepatic Resection of HCC in Cirrhotic Patients 864 resections for HCC in CPT A cirrhosis, INT-Milan and Bologna University, Death due to tumor recurrence (59.6%) vs liver failure (19.9% ) Deaths From Liver Failure Deaths From Tumor Recurrence 16 months Cucchetti A et al in press
46 HCC Decreases the Chance of Successful HCV Therapy with Direct-acting Antivirals 12-wk failure: 21% HCC vs 12% non HCC (P = 0.009) Prenner S B et al J Hepatol 2017; 66 :
47 Association Between IFN and Improved HCV-related Outcomes Following Ablation or Resection HCC Recurrence Overall Survival Singal et al, Aliment Pharmacol Ther 2010;32:
48 Risk Factors for HCC Development in HCV Patients Following SVR To IFN Chronic hepatitis + SVR Liver cirrhosis + SVR Chronic hepatitis + Non-SVR Liver cirrhosis + Non-SVR Arase et al, Hepatology 2013;57:
49 Better Outcome of Radical Therapy of HCC in SVR Than in Non-SVR Patients 1061 patients with HCV cirrhosis treated in Milan and Palermo 181(17%) achieved a SVR. HCC developed in 20 SVR patients vs 194 non SVR patients. Overall survival Time to decompensation Time to HCC recurrence Bruno S et al Liver Intern in press
XVII Annual Meeting of Hepatology
XVII Annual Meeting of Hepatology Malaga 18,19 May 2018 Chronic Hepatitis C and HCC : What is new? Massimo Colombo, MD Head,Humanitas Clinical and Research Center, Rozzano, Italy. Chairman,EASL International
More information3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice
3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice Rome, 13 December 2013 Management and monitoring of HCC in the future era of DAA s Prof. Massimo Colombo Chairman Department of Liver,
More informationHCV care after cure. This program is supported by educational grants from
HCV care after cure This program is supported by educational grants from Raffaele Bruno,MD Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia Fondazione IRCCS Policlinico
More informationWhite Nights of Hepatology 2016
White Nights of Hepatology 2016 Saint Petersburg, 3 June 2016 Long-term treatment of Chronic hepatitis B - a key to HCC prevention Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow
More information9th Paris Hepatitis Conference
9th Paris Hepatitis Conference Paris, 12 January 2016 Treatment of hepatocellular carcinoma: beyond international guidelines Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationHepatitis Alert: Management of Patients With HCV Who Have Achieved SVR
Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationThe Impact of DAA on HCC Occurrence
The Impact of DAA on HCC Occurrence Professeur Didier Samuel Centre Hépatobiliaire Inserm-Paris Sud Research Unit 1193 Departement Hospitalo Universitaire Hepatinov Hôpital Paul Brousse Université Paris
More informationFollow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France
9th Paris Hepatitis Conference, January 11-12, 2016 Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France Disclosures
More information6 Riunione Monotematica A.I.S.F NASH malattia epatica, oncologica e cardiovascolare
6 Riunione Monotematica A.I.S.F. 2015 NASH malattia epatica, oncologica e cardiovascolare Modena, 9 ottobre 2015 Massimo Colombo NAFLD e HCC: caratteristiche distintive Chairman Department of Liver, Kidney,
More informationHepatocellular Carcinoma Surveillance
Amit G. Singal, MD, MS Hepatocellular Carcinoma Surveillance Postgraduate Course: Challenges in Management of Common Liver Diseases 308 1 Patient Case 69 year-old otherwise healthy male with compensated
More informationLa gestione corrente dell infezione cronica da HCV: la progressione verso la cirrosi. Simona Landonio I Div Mal inf H Sacco Milano
La gestione corrente dell infezione cronica da HCV: la progressione verso la cirrosi Simona Landonio I Div Mal inf H Sacco Milano HCV Natural History Viganò M et al Gastroenterology 27;133:835-842 Overall
More informationScreening for HCCwho,
Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology
More informationThe Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University
The Effect of Antiviral Therapy on Liver Fibrosis in CHC Jidong Jia Beijing Friendship Hospital, Capital Medical University 2016-5-29 1 Disclosure Consultation for Abbvie, BMS, Gilead, MSD, Novartis and
More informationThe impact of the treatment of HCV in developing Hepatocellular Carcinoma
The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University
More informationHepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany
Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany PHC 2018 - www.aphc.info Disclosures Advisory boards:
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationA One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran
A One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran Teheran, 22 July 2016 Massimo Colombo Treatment of HCV genotype 1 & 4 with DAAs
More informationANTIVIRAL THERAPY FOR HCV. Alfredo Alberti
CLINICAL IMPACT OF SVR AFTER ANTIVIRAL THERAPY FOR HCV Alfredo Alberti Department of Histology,Microbiology and Medical Biotechnologies Molecular Hepatology Unit Venetian Institute of Molecular Medicine
More informationThe Short-Term Incidence of Hepatocellular Carcinoma Is Not Increased After Hepatitis C Treatment with Direct-Acting Antivirals: An ERCHIVES Study
The Short-Term Incidence of Hepatocellular Carcinoma Is Not Increased After Hepatitis C Treatment with Direct-Acting Antivirals: An ERCHIVES Study DK Li, YJ Ren, DS Fierer, S Rutledge, OS Shaikh, V Lo
More informationImpatto della clearance virale e rischio di carcinoma epatocellulare
EPATITE CRONICA DA HCV: Impatto della clearance virale e rischio di carcinoma epatocellulare Rodolfo Sacco, M.D., PhD Direttore U.O.C. Gastroenterologia ed Endoscopia Digestiva A.O.U. Ospedali Riuniti"
More information4th International HIV/Viral Hepatitis Co-Infection Meeting
4th International HIV/Viral Hepatitis Co-Infection Meeting The Rocky Road to Viral Hepatitis Elimination: Assuring access to antiviral therapy for ALL co-infected patients from low to high income settings
More informationHepatitis C - results in real life
Hepatitis C - results in real life Robert Flisiak Department of Infectious Diseases and Hepatology Medical University of Białystok, Poland 10th PHC Paris, 30-31 January 2017 Disclosures Advisor and/or
More information7th Paris Hepatitis Conference
7th Paris Hepatitis Conference Paris, 14 January 2014 Impact of HBV therapy on the incidence of hepatocellular carcinoma Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units
More informationHepatitis C Highlights from ILC / EASL 2016
Hepatitis C Highlights from ILC / EASL 2016 VIII International Update Workshop in Hepatology Curitiba, 26.08.2016 Christoph Sarrazin St. Josefs-Hospital Wiesbaden and Goethe-University, Frankfurt am Main
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More information«Εκτίμηση κινδφνου ανάπτυξης ΗΚΚ σε ασθενείς με HCV λοίμωξη» Evaluation of HCC risk in HCV patients
«Εκτίμηση κινδφνου ανάπτυξης ΗΚΚ σε ασθενείς με HCV λοίμωξη» Evaluation of HCC risk in HCV patients Δημήτρησ Ν. αμωνάκησ Γαςτρεντερολογική κλινική Πανεπιςτημίου Κρήτησ Outline Epidemiology Risk factors
More informationCon: Treating Hepatitis C Virus With Direct-Acting Antivirals: Fear Not the Perceived Threat of Hepatocellular Carcinoma
CONTROVERSIES IN LIVER TRANSPLANTATION Con: Treating Hepatitis C Virus With Direct-Acting Antivirals: Fear Not the Perceived Threat of Hepatocellular Carcinoma Neil Mehta and Francis Y. Yao Division of
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationTreatment of chronic hepatitis delta Case report
Treatment of chronic hepatitis delta Case report George Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National and Kapodistrian University of Athens, Director of Academic Department
More informationAntiviral Therapy and Liver Cancer
Antiviral Therapy and Liver Cancer St. Petersburg, 070613 Markus Peck-Radosavljevic Gastroenterologie & Hepatologie AKH & Medizinische Universität Wien HCC Study Group Medizinische Universität Wien Prevention
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationSpecial developments in the management of Hepatitis C. Disclosures
Special developments in the management of Hepatitis C Sandeep Mukherjee,MD Division of Gastroenterology CHI Health and Creighton University Medical Center Omaha, NE 68154 Sandeep.Mukherjee@alegent.org
More informationAccepted Manuscript. Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming?
Accepted Manuscript Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming? Qing-Lei Zeng, Zhi-Qin Li, Hong-Xia Liang, Guang-Hua Xu, Chun-Xia
More informationHepatitis C in Disclosures
Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy
New York State HCV Provider Webinar Series Side Effects of Therapy Objectives Understand the basics of HCV therapy Review the currently available regimens for treatment of HCV Appreciate side effects related
More informationAASLD Washington DC, USA Dr. Alexander Kim Chief Vascular and Interventional Radiology, Medstar Georgetown University Hospital
AASLD 2017 - Washington DC, USA Dr. Alexander Kim Chief Vascular and Interventional Radiology, Medstar Georgetown University Hospital THE CHANGING LANDSCAPE IN THE TREATMENT OF HCC DISCLAIMER Please note:
More informationManagement of HepatoCellular Carcinoma
9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationIS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationHepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan;
Editorial The unexpected high risk of occurrence or recurrence of hepatocellular carcinoma after successful antiviral therapy with interferon-free direct-acting antivirals Ming-Lung Yu 1,2,3, Chung-Feng
More informationHow do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu
How do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu Seng Gee Lim Chairman, APASL Liver Week 2013 Professor of Medicine Dept of Gastroenterology and Hepatology NUHS, Singapore Disclosures
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationDAAs in the era of decompensated liver disease. Piero L. Almasio University of Palermo
DAAs in the era of decompensated liver disease Piero L. Almasio University of Palermo piero.almasio@unipa.it HCV therapy in the era of interferon based therapy Priority Compensated cirrhosis Decompensated
More informationNUCs for Chronic Hepatitis B. Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona.
NUCs for Chronic Hepatitis B Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona. Spain Disclosures Advisory board of, and/or, received speaker fee from
More informationMassimo Puoti SC Malattie Infettive ASST GRANDE OSPEDALE METROPOLITANO NIGUARDA MILANO. Beyond HCV cure: reversibility of liver damage
Massimo Puoti SC Malattie Infettive ASST GRANDE OSPEDALE METROPOLITANO NIGUARDA MILANO Beyond HCV cure: reversibility of liver damage Beyond HCV Cure: reversibility of liver damage Regression of necroinflammatory
More informationHCV Viremia Was Associated With Increased Mortality in a Prospective Taiwanese Cohort Study
Tram T. Tran, MD, FACG Approach to HCV Treatment in Patients with HCC Tram T. Tran, MD, FACG Professor of Medicine Medical Director, Liver Transplant Cedars Sinai Medical Center Natural History of HCV
More informationIL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE?
IL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE? Francesco Paolo Russo Department of Surgery, Oncology and Gastroenterology Multivisceral/ Gastroenterology Section University
More informationMeet the Professor: HIV/HCV Coinfection
Meet the Professor: HIV/HCV Coinfection Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Division of Infectious Diseases Center for Clinical Epidemiology and Biostatistics University
More informationHBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But
HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But Hospital Universitario Valle Hebron and Ciberehd del Insttuto Carlos III. Barcelona. Spain Disclosures Advisory board of,
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More informationProfessor Norbert Bräu
Sixth Annual BHIVA Conference for the Management of HIV/Hepatitis Co-Infection in collaboration with BASL and BVHG Professor Norbert Bräu James J Peters VA Medical Center, New York, USA COMPETING INTEREST
More informationHepatitis C and HIV. Stanislas Pol
Hepatitis C and HIV Stanislas Pol Unité d Hépatologie, Hôpital Cochin Inserm U1223 & USM20 Institut Pasteur Université Paris Descartes Paris, France stanislas.pol@cch.aphp.fr Lisboa, 30 January 2017 Disclosures
More informationPatients with compensated cirrhosis: how to treat and follow-up
Patients with compensated cirrhosis: how to treat and follow-up Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Universitätsklinikum Leipzig Leber- und Studienzentrum
More informationTHE CHANGING LANDSCAPE IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA (HCC)
MEETING SUMMARY EASL 2017, AMSTERDAM, THE NETHERLANDS APRIL 19 TH TO 23 RD 2017 DR JEAN-CHARLES NAULT JEAN VERDIER HOSPITAL, BONDY, FRANCE THE CHANGING LANDSCAPE IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationSEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA
SEQUENCING OF HCC TREATMENT Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA February 2018 DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationHepatocellular Carcinoma: Transplantation, Resection or Ablation?
Hepatocellular Carcinoma: Transplantation, Resection or Ablation? Roberto Gedaly MD Chief, Abdominal Transplantation Transplant Service Line University of Kentucky Nothing to disclose Disclosure Objective
More information3/22/2017. I will be discussing off label/investigational use of tivantinib for hepatocellular carcinoma.
Grant/Research Support - AbbVie, Conatus, Hologic, Intercept, Genfit, Gilead, Mallinckrodt, Merck, Salix, Shire, Vital Therapies Consultant AbbVie, Gilead, Merck Member, Scientific Advisory Board Vital
More informationSteatosi epatica ed HCV
Steatosi epatica ed HCV Malattie delle vie biliari ed Epatologia Rho, Auditorium Padri Oblati, 11 Novembre 2006 Piero L. Almasio Università di Palermo HISTOPATHOLOGY Steatosis and accelerated fibrogenesis:
More informationHCV Treatment in 2016: is there still a role for IFNa and ribavirin?
HCV Treatment in 2016: is there still a role for IFNa and ribavirin? Heiner Wedemeyer Hannover Medical School Germany 1 Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, AbbVie,
More informationHCC Prevention. Jee-Fu Huang. Kaohsiung Municipal Hsiao-Kang Hospital, KMUH Kaohsiung (Takao), Taiwan. TCC, HCC Prevention, 26 Nov, 2011
HCC Prevention Jee-Fu Huang Kaohsiung Municipal Hsiao-Kang Hospital, KMUH Kaohsiung (Takao), Taiwan TCC, HCC Prevention, 26 Nov, 2011 1 Outline Pathogenic and Risk Factors HBV HCV Primary Secondary Primary
More informationBackground. ΝΑ therapy in CHBe- until HBsAg clearance. (EASL guidelines 2012)
Interferon-induced protein 10 (IP10) at discontinuation of effective entecavir (ETV) or tenofovir (TDF) therapy cannot predict subsequent relapses in non-cirrhotic HBeAgnegative chronic hepatitis B (CHBe-)
More informationDon t interfere My first choice is always nucs!
Don t interfere My first choice is always nucs! Robert G Gish MD Professor Consultant Stanford University Medical Director, Hepatitis B Foundation Singapore Viral Hepatitis Meeting 2014 1 Disclosures Dr
More informationAASLD, Boston, USA, 10 th November 2014 [oral presentation]
Effects of Sustained Virological Response on the of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 34,563 patients with Hepatitis C infection. Andrew
More informationMolecular signature for management of hepatocellular carcinoma
Molecular signature for management of hepatocellular carcinoma Yujin Hoshida, MD, PhD Liver Cancer Program, Tisch Cancer Institute Division of Liver Diseases, Department of Medicine Icahn School of Medicine
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationLife After SVR for Cirrhotic HCV
Life After SVR for Cirrhotic HCV KIM NEWNHAM MN, NP CIRRHOSIS CARE CLINIC UNIVERSITY OF ALBERTA Objectives To review the benefits of HCV clearance in cirrhotic patients To review some of the emerging data
More informationHEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT
HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%
More informationHCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
More informationHEPATITIS B: WHO AND WHEN TO TREAT?
HEPATITIS B: WHO AND WHEN TO TREAT? George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department of
More informationPersonalised Treatment with Telaprevir in Graham R Foster Professor of Hepatology Queen Marys University of London
Personalised Treatment with Telaprevir in 2014 Graham R Foster Professor of Hepatology Queen Marys University of London Telaprevir in 2014 Disclaimers I have received funds from: BI, BMS, Janssen, Novarts,
More informationLiver Pathology and the Clinician in 2015: At the Crossroads. Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York
Liver Pathology and the Clinician in 2015: At the Crossroads Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York DISCLOSURES Consultant for: Salix Merck Gilead BMS Synageva Research funding:
More informationThe Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:
The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: Certified by: Provided by: Endorsed by: Hepatocellular Carcinoma HCC: Age
More informationB C Outlines. Child-Pugh scores
B C 2016-12-09 Outlines Child-Pugh scores CT MRI Fibroscan / ARFI Histologic Scoring Systems for Fibrosis Fibrosis METAVIR Ishak None 0 0 Portal fibrosis (some) 1 1 Portal fibrosis (most) 1 2 Bridging
More informationASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT
ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT Mitchell L Shiffman, MD Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationDetection and significance of PD-1.3 SNP (rs ) and IL28B SNP (rs ) in patients with current or past hepatitis B virus (HBV) infection
Detection and significance of PD-1.3 SNP (rs11568821) and IL28B SNP (rs12979860) in patients with current or past hepatitis B virus (HBV) infection Asterios Saitis 1, Nikolaos K. Gatselis 1, Kalliopi Azariadi
More informationAbstract and Introduction. Patients and Methods. M. Hedenstierna; A. Nangarhari; A. El-Sabini; O. Weiland; S.
www.medscape.com Cirrhosis, High Age and High Body Mass Index Are Risk Factors for Persisting Advanced Fibrosis After Sustained Virological Response in Chronic Hepatitis C M. Hedenstierna; A. Nangarhari;
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Sovaldi (sofosbuvir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/8/2014 1. Indications Drug Name: Sovaldi
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationShould Elderly CHC Patients (>70 years old) be Treated?
Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,
More informationProgression of the disease. Heiner Wedemeyer
Progression of the disease Heiner Wedemeyer Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, Abvie, Biolex, BMS, Boehringer Ingelheim, Eiger, Gilead, ITS, JJ/Janssen-Cilag, Medgenics,
More informationProfessor Mark Nelson. Chelsea and Westminster Hospital, London, UK
Professor Mark Nelson Chelsea and Westminster Hospital, London, UK Treatment should be prioritized Treatment Indicated All naive and experienced pts with liver disease Prioritized Pts with fibrosis (F3)
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationIs Treatment cost effective HCV and Organ Transplantation
Is Treatment cost effective HCV and Organ Transplantation Dr Kosh Agarwal Institute of Liver Studies King s College Hospital Barcelona 2016 Disclosures: BoJo Pharma support: AbbVie/Achillion/ Astellas/
More informationHCC: Is it an oncological disease? - No
June 13-15, 2013 Berlin, Germany Prof. Oren Shibolet Head of the Liver Unit, Department of Gastroenterology Tel-Aviv Sourasky Medical Center and Tel-Aviv University HCC: Is it an oncological disease? -
More informationManagement of HCV in Decompensated Liver Disease
Management of HCV in Decompensated Liver Disease Michael P. Manns Hannover Medical School (MHH) Department of Gastroenterology, Hepatology and Endocrinology Helmholtz Center for Infection Research (HZI),
More informationUpdate in hepatitis C virus infection
Update in hepatitis C virus infection Eoin Feeney Consultant in Infectious Diseases St. Vincent s University Hospital Overview Natural history Diagnosis, screening, staging Management Barriers going forward
More information